| Filed On | Filing |
|---|---|
| 08 Mar 2024 | EFFECT |
| 26 Jan 2024 | 15-12G |
| 26 Jan 2024 | S-8 POS |
| 26 Jan 2024 | S-8 POS |
| 26 Jan 2024 | POS AM |
| 26 Jan 2024 | 8-K: Submission of Matters to a Vote of Security Holders |
| 27 Dec 2023 | 25-NSE |
| 12 Dec 2023 | DEFA14A |
| 12 Dec 2023 | DEF 14A |
| 11 Dec 2023 | SC 13G/A |
| 04 Dec 2023 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 01 Dec 2023 | PRE 14A |
| 21 Nov 2023 | 8-K: Departure/Election of Directors or Officers; Compensation; Other Events |
| 13 Nov 2023 | SC 13G/A |
| 09 Nov 2023 | 10-Q |
| 08 Nov 2023 |
Form 4: Bodmer Mark, CSO, President of R&D
Received 6,625 shares by exercise or conversion · Sold 3,163 shares ($1.04K) |
| 08 Nov 2023 |
Form 4: McHale Duncan, Chief Medical Officer
Received 6,500 shares by exercise or conversion · Sold 3,103 shares ($1.02K) |
| 08 Nov 2023 |
Form 4: Gill Simba, Director
Received 1,172 shares by exercise or conversion · Sold 172 shares ($56.8) |
| 08 Nov 2023 |
Form 4: Thorell Marella, Chief Financial Officer
Received 6,500 shares by exercise or conversion · Sold 1,811 shares ($598) |
| 03 Nov 2023 |
Form 4: Bodmer Mark, CSO, President of R&D
Received 12,500 shares by exercise or conversion · Sold 6,854 shares ($2.26K) |
Loading...
